Angus Dalgleish

Q: What Schools Are Affiliated With Angus Dalgleish

Angus Dalgleish is affiliated with the following schools: Institute of Cancer Research, University College London, St George's, University of London, Nottingham Trent University, University of Genoa

Angus Dalgleish's AcademicInfluence.com Rankings

Angus Dalgleish

Medical

#794

World Rank

#1042

Historical Rank

Oncology

#36

World Rank

#38

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Angus Dalgleish Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Angus George Dalgleish FRCP FRCPath FMedSci is a professor of oncology at St George's, University of London, best known for his contributions to HIV/AIDS research. Dalgleish stood in 2015 for Parliament as a UKIP candidate.

(See a Problem?)

Angus Dalgleish's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus (1984) (3590)
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain (1986) (2039)
Kaposi's sarcoma. (1991) (845)
Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. (2005) (845)
The evolution of thalidomide and its IMiD derivatives as anticancer agents (2004) (715)
SLIM DISEASE: A NEW DISEASE IN UGANDA AND ITS ASSOCIATION WITH HTLV-III INFECTION (1985) (570)
Chronic immune activation and inflammation as the cause of malignancy (2001) (562)
In vivo cellular tropism of human T-cell leukemia virus type 1 (1990) (435)
Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients (1985) (426)
The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. (1996) (360)
Epitopes of the CD4 antigen and HIV infection. (1986) (359)
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells (2009) (352)
Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells (1989) (347)
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. (2004) (307)
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects (2002) (301)
Variable and conserved neutralization antigens of human immunodeficiency virus (1986) (292)
Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses (2009) (265)
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. (2005) (258)
HIV infection does not require endocytosis of its receptor, CD4 (1988) (228)
Origins of HIV and the Evolution of Resistance to AIDS (2006) (226)
PREVALENCE OF ANTIBODY TO HUMAN T-LYMPHOTROPIC VIRUS TYPE III IN AIDS AND AIDS-RISK PATIENTS IN BRITAIN (1984) (226)
The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. (2000) (193)
Human immunodeficiency virus infection of monocytic and T-lymphocytic cells: receptor modulation and differentiation induced by phorbol ester. (1987) (187)
Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. (2002) (178)
Thalidomide and its analogues have distinct and opposing effects on TNF‐α and TNFR2 during co‐stimulation of both CD4+ and CD8+ T cells (2002) (158)
Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity1 (2002) (158)
Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers (2004) (146)
Thalidomide as an emerging immunotherapeutic agent. (1999) (144)
Heat shock proteins refine the danger theory (2000) (133)
Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy (2002) (126)
Phase I/II study of topical imiquimod and intralesional interleukin‐2 in the treatment of accessible metastases in malignant melanoma (2007) (125)
Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom. (1989) (123)
LOW PREVALENCE IN THE UK OF HTLV-I AND HTLV-II INFECTION IN SUBJECTS WITH AIDS, WITH EXTENDED LYMPHADENOPATHY, AND AT RISK OF AIDS (1984) (123)
Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-γ and altered expression of Bcl-2/Bax (2002) (120)
Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. (1988) (120)
CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. (1998) (118)
Immunotherapeutic potential of whole tumour cells (2002) (117)
HTLV-III SEROLOGY DISTINGUISHES ATYPICAL AND ENDEMIC KAPOSI'S SARCOMA IN AFRICA (1985) (112)
Viruses and cancer. (1991) (112)
ANTIBODY TO HUMAN T-LYMPHOTROPIC VIRUS TYPE 1 IN WEST-INDIAN-BORN UK RESIDENTS WITH SPASTIC PARAPARESIS (1987) (109)
Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate‐pulsed cells: a phase I/II study (2004) (109)
HIV envelope glycoprotein, antigen specific T-cell responses, and soluble CD4 (1990) (106)
Infection, immunoregulation, and cancer (2011) (104)
Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. (2000) (103)
T-regulatory cell modulation: the future of cancer immunotherapy? (2009) (102)
The Combination of Cannabidiol and Δ9-Tetrahydrocannabinol Enhances the Anticancer Effects of Radiation in an Orthotopic Murine Glioma Model (2014) (101)
INACTIVATION OF HIV BY NONOXYNOL-9 (1988) (100)
Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection (2000) (97)
Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide. (2011) (97)
Does the HIV envelope induce a chronic graft-versus-host-like disease? (1992) (96)
Overview of Tumor Cell–Based Vaccines (2006) (95)
AIDS pathogenesis: HIV envelope and its interaction with cell proteins. (1990) (90)
T-cell receptor variable gene products and early HIV-1 infection (1992) (90)
Review article: immune suppression and colorectal cancer (2006) (87)
Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). (1998) (87)
Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives. (1995) (80)
Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases (2017) (79)
Priming of human CD4+ antigen-specific T cells to undergo apoptosis by HIV-infected monocytes. A two-step mechanism involving the gp120 molecule. (1997) (78)
CD40 ligation for immunotherapy of solid tumours. (2001) (78)
Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. (1999) (77)
Enhanced cross‐priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide (2013) (77)
Angiogenesis as a biomarker and target in cancer chemoprevention. (2001) (74)
Cellular immunology of HIV-infection. (1988) (73)
Impact of surgery on immunologic function: comparison between minimally invasive techniques and conventional laparotomy for surgical resection of colorectal tumors. (2009) (71)
Inflammation and Cancer (2006) (71)
Seven genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis: a detailed analysis of gene networks and clinical phenotypes (2007) (67)
Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells (2011) (67)
The naive repertoire of human T helper cells specific for gp120, the envelope glycoprotein of HIV. (1991) (66)
Differential and antagonistic effects of 9- cis -retinoic acid and vitamin D analogues on pancreatic cancer cells in vitro (2000) (66)
A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. (1996) (65)
New concepts in AIDS pathogenesis. (1993) (65)
NEUTRALISATION OF HIV ISOLATES BY ANTI-IDIOTYPIC ANTIBODIES WHICH MIMIC THE T4 (CD4) EPITOPE: A POTENTIAL AIDS VACCINE (1987) (64)
Human retroviruses. (1985) (64)
The interleukins in acquired disease. (1988) (63)
Mechanisms of action of tasquinimod on the tumour microenvironment (2013) (63)
The role of host immune responses in determining the outcome of HIV infection. (1996) (62)
Whole-cell vaccines: A failure or a success waiting to happen? (2010) (62)
Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. (2000) (58)
The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies (2011) (57)
Adult coeliac disease (1996) (57)
Recent advances and developments in treatment strategies against pancreatic cancer. (2009) (57)
Immunotherapeutic and antitumour potential of thalidomide analogues (2001) (56)
Immunological effects of thalidomide and its chemical and functional analogs. (2002) (53)
The relevance of non-linear mathematics (chaos theory) to the treatment of cancer, the role of the immune response and the potential for vaccines. (1999) (53)
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients (2015) (52)
ISOLATION OF RETROVIRUSES FROM TWO PATIENTS WITH "COMMON VARIABLE" HYPOGAMMAGLOBULINAEMIA (1986) (52)
Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy (2011) (52)
Alloimmunization as an AIDS vaccine? (1993) (52)
Inflammation and cancer: the role of the immune response and angiogenesis. (2006) (52)
Topical imiquimod and intralesional interleukin‐2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma (2008) (52)
Bleomycin pulmonary toxicity: its relationship to renal dysfunction. (1984) (51)
Anticancer effects of phytocannabinoids used with chemotherapy in leukaemia cells can be improved by altering the sequence of their administration. (2017) (51)
Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. (2006) (50)
Improving the efficacy of cancer immunotherapy. (2009) (50)
A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins. (2003) (49)
HIV immunopathogenesis and strategies for intervention. (2008) (49)
Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). (2009) (48)
Evaluation of hypochlorite-releasing disinfectants against the human immunodeficiency virus (HIV). (1990) (48)
Doxycycline induces caspase‐dependent apoptosis in human pancreatic cancer cells (2007) (48)
Anti-idiotypic antibodies as immunogens: idiotype-based vaccines. (1988) (48)
In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents (2011) (47)
Gene therapy for prostate cancer. (1999) (46)
Lenalidomide: a novel anticancer drug with multiple modalities (2009) (45)
Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells (2013) (45)
Thalidomide-derived immunomodulatory drugs as therapeutic agents (2004) (45)
Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol (2018) (44)
The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival (2006) (43)
PCR Analysis of DNA from Multiple Sclerosis Patients for the Presence of HTLV-I (1989) (42)
The T4 glycoprotein is a cell-surface receptor for the AIDS virus. (1986) (42)
Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine (1996) (41)
Gene therapy for prostate cancer. (1996) (41)
Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine (1999) (41)
Retinoic Acid Enhances the Cytotoxic Effects of Gemcitabine and Cisplatin in Pancreatic Adenocarcinoma Cells (2001) (41)
HTLV-1 infection in tropical spastic paraparesis: lymphocyte culture and serologic response. (1988) (41)
T regulatory cells, the evolution of targeted immunotherapy. (2010) (41)
A proposed molecular model for the carboxy terminus of HIV-1 gp120 showing structural features consistent with the presence of a T-cell alloepitope. (1991) (41)
The immune response to HIV: potential for immunotherapy? (1995) (40)
Therapeutic potential of TNF-α inhibitors old and new (1997) (40)
Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors (2017) (40)
Rationale for combining immunotherapy with chemotherapy. (2015) (39)
Cell based cancer vaccines: regulatory and commercial development. (2007) (39)
Dendritic cells infected in vitro with human T cell leukaemia/lymphoma virus type‐1 (HTLV‐1); enhanced lymphocytic proliferation and tropical spastic paraparesis (1993) (39)
Failure of ADCC to predict HIV‐associated disease progression or outcome in a haemophiliac cohort (1990) (38)
Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection. (1996) (38)
Characteristics and Growth Patterns of Human Peritoneal Mesothelial Cells: Comparison Between Advanced Epithelial Ovarian Cancer and Non-Ovarian Cancer Sources (1999) (38)
An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer. (2008) (38)
Studies in healthy human T‐cell‐leukemia lymphoma virus (HTLV‐I) carriers from the Caribbean (1986) (38)
Coeliac disease presenting with cerebellar degeneration. (1991) (37)
A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines. (1997) (37)
HTLV-I infection and neurological disease in Rio de Janeiro. (1992) (36)
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial (2018) (36)
Thalidomide analogs as emerging anti-cancer drugs (2003) (36)
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial (2018) (36)
Cancer immunotherapy: an embarrassment of riches? (2003) (36)
Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs) (2009) (35)
Infection of B lymphocytes by the human immunodeficiency virus and their susceptibility to cytotoxic cells (1988) (34)
Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. (2015) (34)
Viruses and multiple sclerosis (1997) (33)
CLINICAL FINDINGS AND SEROLOGICAL EVIDENCE OF HTLV-III INFECTION IN HOMOSEXUAL CONTACTS OF PATIENTS WITH AIDS AND PERSISTENT GENERALISED LYMPHADENOPATHY IN LONDON (1984) (33)
Alloactivated cytotoxic T cells recognize the carboxy‐terminal domain of human immunodeficiency virus‐1 gp120 envelope glycoprotein (1993) (32)
Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells (2018) (32)
An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma. (2012) (32)
Human immunodeficiency viruses: neutralization and receptors. (1988) (32)
Cannabis-derived substances in cancer therapy--an emerging anti-inflammatory role for the cannabinoids. (2010) (32)
Cancer vaccines as a therapeutic modality: the long trek (2006) (31)
The case for therapeutic vaccines. (1996) (31)
The T4 molecule: function and structure. (1986) (31)
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer (2016) (31)
Screening for prolonged incubation of HTLV-I infection in British and Jamaican relatives of British patients with tropical spastic paraparesis. (1990) (31)
Characteristics and growth patterns of human peritoneal mesothelial cells: comparison between advanced epithelial ovarian cancer and non-ovarian cancer sources. (1999) (31)
Angiogenesis inhibitors in cancer therapy. (2003) (31)
A search for retrovirus infection in systemic lupus erythematosus and rheumatoid arthritis. (1988) (31)
13-cis-Retinoic acid in combination with gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer--report of a pilot phase II study. (2007) (30)
Lenalidomide enhances the anti‐prostate cancer activity of docetaxel in vitro and in vivo (2012) (30)
Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complex. (1987) (30)
Allogeneic whole‐tumour cell vaccination in the rat model of prostate cancer (2000) (30)
Lenalidomide: a novel anticancer drug with multiple modalities. (2009) (30)
INHIBITION OF HIV REPLICATION IN VITRO BY FUSIDIC ACID (1987) (30)
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer (2016) (28)
Surgical Management of Intraabdominal Metastases From Melanoma: Role of the Neutrophil to Lymphocyte Ratio as a Potential Prognostic Factor (2014) (28)
Enhancing the activity of cannabidiol and other cannabinoids in vitro through modifications to drug combinations and treatment schedules. (2013) (28)
Current status and future applications of cellular therapies for cancer. (2011) (28)
Elevated serum levels of soluble interleukin‐2 receptor, neopterin and β‐2‐microglobulin in idiopathic dilated cardiomyopathy: relation to disease severity and autoimmune pathogenesis (2001) (28)
Dendritic cells are potent antigen-presenting cells for in vitro induction of primary human CD4+ T-cell lines specific for HIV gp120. (1994) (27)
Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2′-Deoxycytidine (2011) (27)
The effect of colorectal cancer upon host peripheral immune cell function (2009) (27)
Immune reconstitution in HAART-treated children with AIDS (1998) (27)
Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: implications for gene therapy strategies (2003) (27)
How do human immunodeficiency viruses enter cells? (1987) (26)
Inhibition of p38 MAP kinase during cellular activation results in IFN‐γ‐dependent augmentation of IL‐12 production by human monocytes/macrophages (2001) (26)
Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies. (2011) (26)
A randomized phase II trial of SRL172 (Mycobacterium vaccae) ± low-dose interleukin-2 in the treatment of metastatic malignant melanoma (2003) (25)
HIV and the new viruses (1999) (25)
A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: differences in action in vivo and in vitro (2010) (25)
Role of flanking variable sequences in antigenicity of consensus regions of HIV gp120 for recognition by specific human T helper clones (1993) (25)
Interleukin-10-induced HIV-1 expression is mediated by induction of both membrane-bound tumour necrosis factor (TNF)-alpha and TNF receptor type 1 in a promonocytic cell line. (1996) (24)
Tumor antigens as surrogate markers and targets for therapy and vaccines. (2007) (24)
Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer. (1998) (24)
Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model (1998) (23)
Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy. (2016) (23)
Biovacc-19: A Candidate Vaccine for Covid-19 (SARS-CoV-2) Developed from Analysis of its General Method of Action for Infectivity (2020) (23)
Cryopreservation of immature monocyte-derived dendritic cells results in enhanced cell maturation but reduced endocytic activity and efficiency of adenoviral transduction. (2003) (23)
Anti-CD4 autoantibodies and screening for anti-idiotypic antibodies to anti-CD4 monoclonal antibodies in HIV-seropositive people. (1990) (23)
Possession of human leucocyte antigen DQ6 alleles and the rate of CD4 T‐cell decline in human immunodeficiency virus‐1 infection (2004) (23)
Repertoire breadth of human CD4+ T cells specific for HIV gp120 and p66 (primary antigens) or for PPD and tetanus toxoid (secondary antigens) (1998) (23)
Eosinophilic folliculitis occurring after bone marrow autograft in a patient with non‐Hodgkin's lymphoma (1994) (22)
HTLV-I AND NEUROLOGICAL DISEASE IN SOUTH INDIA (1989) (22)
Differences in affinity of anti-CD4 monoclonal antibodies predict their effects on syncytium induction by human immunodeficiency virus. (1990) (22)
The thalidomide analogue CC‐3052 inhibits HIV‐1 and tumour necrosis factor‐alpha (TNF‐α) expression in acutely and chronically infected cells in vitro (2000) (22)
Angiogenesis and the immune response as targets for the prevention and treatment of colorectal cancer (review). (2003) (21)
Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer. (2012) (21)
Bladder and prostate cancer screening for human papillomavirus by polymerase chain reaction: conflicting results using different annealing temperatures. (1993) (21)
HIV induced AIDS and related cancers: chronic immune activation and future therapeutic strategies. (2008) (21)
Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition (2016) (21)
T-LYMPHOMA ASSOCIATED WITH HTLV-I OUTSIDE THE CARIBBEAN AND JAPAN (1985) (21)
DO HUMAN T‐LYMPHOTROPHIC VIRUSES (HTLVs) AND OTHER ENVELOPED VIRUSES INDUCE AUTOIMMUNITY IN MULTIPLE SCLEROSIS? (1987) (20)
Investigation of the Mechanisms by Which EB1089 Abrogates Apoptosis Induced by 9-cis Retinoic Acid in Pancreatic Cancer Cells (2006) (20)
Recent developments in antiangiogenic therapy (2002) (20)
The common heat shock protein receptor CD91 is up‐regulated on monocytes of advanced melanoma slow progressors (2004) (20)
Investigator-initiated trials of targeted oncology agents: why independent research is at risk? (2010) (19)
Zoledronic acid causes γδ T cells to target monocytes and down‐modulate inflammatory homing (2014) (19)
AIDS And the New Viruses (1990) (19)
Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques (2001) (19)
Comparison of IL-2- and IL-4-transfected B16-F10 cells with a novel oil-microemulsion adjuvant for B16-F10 whole cell tumour vaccine. (1996) (18)
The role of IL-2 in gene therapy. (1994) (18)
Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents. (2003) (18)
Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines (2001) (18)
Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex viral thymidine kinase/ganciclovir suicide gene therapy (2005) (17)
The role of immunotherapy for urological tumours. (1997) (17)
Inhibitory activity of HIV envelope gp120 dominates over its antigenicity for human T cells (1992) (17)
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma (2020) (17)
What is the role of autoimmunity in AIDS? (1993) (17)
Advanced breast cancer: response to high dose oral medroxyprogesterone acetate. (1984) (17)
The conserved carboxy terminal region of HIV-1 gp120 is recognized by seronegative HIV-exposed people. (1999) (17)
Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and “New Old Friends” (2020) (17)
Heated tumour cells of autologous and allogeneic origin elicit anti-tumour immunity (2004) (16)
ANTIGEN TEST VERSUS REVERSE TRANSCRIPTASE ASSAY FOR DETECTING HIV (1987) (16)
Why: Gene Therapy? (1997) (16)
Retroviruses and oncogenes. (1989) (16)
AUTOIMMUNE MECHANISMS OF DEPLETION OF CD4 CELLS IN HIV INFECTION (1995) (16)
Antibody-dependent cell-mediated cytotoxicity: comparison between HTLV-I and HIV-1 assays. (1988) (16)
HIV‐induced deletion of antigen‐specific T cell function is MHC restricted (1992) (15)
The Link Between Inflammation and Cancer (2006) (15)
MTT assays can underestimate cell numbers (2009) (15)
Human Peritoneal Mesothelial Cells Display Phagocytic and Antigen-Presenting Functions to Contribute to Intraperitoneal Immunity (2016) (15)
Gene therapy: recent progress in the clinical oncology arena. (2000) (15)
Successful live cell harvest from bisected sentinel lymph nodes research report. (2004) (15)
Advances in prostate cancer immunotherapy. (2002) (15)
The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics (2012) (15)
Potential Applications of Gene Therapy in the Patient with Cancer (2000) (15)
The link between inflammation and cancer : wounds that do not heal (2006) (15)
Neopterin concentrations in serum and cerebrospinal fluid in HTLV-I infected individuals (1992) (15)
Antiproliferative Effects of CC-8062 and CC-8075 in Pancreatic Cancer Cells (2009) (15)
Developments in HIV-1 immunotherapy and therapeutic vaccination (2014) (15)
New approaches to the immunotherapy of cancer (1994) (15)
VEGFr inhibitor YN968D1 xenograft dose response studies against human colon cancer Ls174t and HT29 (2006) (15)
Changes in dendritic cell subsets in the lymph nodes of rhesus macaques after application of glucocorticoids. (2001) (14)
HLA homology within the C5 domain promotes peptide binding by HIV type 1 gp120. (2008) (14)
Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2+ γδ T cell cytotoxicity in a perforin-dependent manner (2017) (14)
Pathogenesis of HIV: non-specific immune hyperactivity and its implications for vaccines. (2008) (14)
Localized conformational changes in the N-terminal domain of CD4 identified in competitive binding assay of monoclonal antibodies and HIV-1 envelope glycoprotein. (1992) (14)
A prostate cancer vaccine comprising whole cells secreting IL-7, effective against subcutaneous challenge, requires local GM-CSF for intra-prostatic efficacy (2009) (14)
Thalidomide analogue CC‐3052 reduces HIV+ neutrophil apoptosis in vitro (2000) (13)
Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity (2018) (13)
Advances in human retroviruses. (1988) (13)
Inactivation of HIV by nonoxynol-9 [letter] (1988) (13)
Primary non-Hodgkin's lymphoma of the thyroid with bone marrow infiltration at presentation. (1995) (13)
Technical challenges facing therapeutic cancer vaccines. (2008) (13)
Novel strains of Salmonella typhimurium as potential vectors for gene delivery. (2004) (13)
The gp120 envelope of HIV‐1 binds peptides in a similar manner to human leukocyte antigens (1995) (13)
The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model (2006) (13)
Low CD4 counts rather than superantigenic‐like effects account for differences in expressed T‐cell receptor (TCR) repertoires between HIV‐1 seropositive long‐term non‐progressors and individuals with progressive disease (1998) (13)
Cryopreserved dendritic cells for intratumoral immunotherapy do not require re-culture prior to human vaccination. (2005) (12)
Assessment of responses of normal human B lymphocytes to different isolates of human immunodeficiency virus: role of normal donor and of cell line used to prepare viral isolate. (1989) (12)
Sequential interleukin-2 and alpha interferon for renal cell carcinoma and melanoma. (1992) (12)
In vitro culture with gemcitabine augments death receptor and NKG2D ligand expression on tumour cells (2019) (12)
Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma (2013) (12)
APPROACHES IN THE TREATMENT OF CANCER (1999) (12)
Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literature (2014) (12)
Role of CD4 in the penetration of cells by HIV. (1991) (12)
Quantitation of HIV-1 activity in tissue culture supernatants: effects of culture condition on syncytial assays and virus production. (1989) (12)
Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer (2018) (12)
Characteristic immunophenotyping artefact seen in patients with anti-mouse immunoglobulin antibodies. (1990) (12)
HIV gp120 plus specific peptides are recognized in a similar manner to specific HLA plus peptide by HLA-restricted antigen-specific T-cell lines. (2000) (11)
Idiotype cascades associated with the CD4-HIV glycoprotein 120 interaction: immunization with anti-idiotypic antibodies induces anti-anti-idiotypic responses with anti-CD4 specificity and in vitro neutralizing activity. (2000) (11)
GROUP SPECIFIC COMPONENT AND HIV INFECTION (1987) (11)
Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study (2014) (11)
An alternative to 51Cr release assay for measurement of natural killer activity in HIV-infected patients. (1996) (11)
The relevance of HIV env/CD4 interactions to the pathogenesis of acquired immune deficiency syndrome. (1989) (11)
Optimisation of a peptide-based indirect ELISA for the detection of antibody in the serum of HIV-1 seropositive patients. (1997) (11)
Acquired immunodeficiency with disseminated cryptococcosis. (1986) (11)
A novel murine model of allogeneic vaccination against prostate cancer (2008) (11)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
Central nervous system echovirus infection in Bruton's X-linked hypogammaglobulinemia. (1985) (11)
REDUCED EXPRESSION OF INTERLEUKIN-2 RECEPTORS IN HYPOGAMMAGLOBULINAEMIA: A POSSIBLE CAUSE OF HIGHER CANCER INCIDENCE (1986) (11)
Role of major histocompatibility complex recognition in the protection and immunopathogenesis of AIDS. Joint Anglo-Italian Workshop on Ponza Island, Italy. (1992) (11)
Supernatants from lymphocytes stimulated with Bacillus Calmette-Guerin can modify the antigenicity of tumours and stimulate allogeneic T-cell responses (2011) (10)
The potential of immunomodulatory drugs in the treatment of solid tumors. (2010) (10)
The gene expression profile of unstimulated dendritic cells can be used as a predictor of function (2012) (10)
Panel of anti-gp120 monoclonal antibodies reacts with same nuclear proteins in uninfected cells as those recognized by autoantibodies from patients with systemic lupus erythematosus. (1994) (10)
Corrigendum: Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer (British Journal of Cancer (2016) 115 (789-796) DOI: 10.1038/bjc.2016.271) (2016) (10)
An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma. (2012) (10)
Vaccines versus immunotherapy: Overview of approaches in deciding between options (2014) (10)
Human T cell leukaemia/lymphoma virus and blood donation. (1993) (10)
How immunotherapy can enhance the response to other modalities and improve outcome and quality of life. (2009) (10)
Cancer vaccines as a therapeutic strategy (2004) (10)
The failure of radical treatments to cure cancer: can less deliver more? (2018) (9)
Poly(I:C)-induced tumour cell death leads to DC maturation and Th1 activation (2011) (9)
Lenalidomide (Revlimid®, CC-5013) and Actimid™ (CC-4047) inhibit the function and expansion of T regulatory (Treg) cells in vitro: Implications for anti-tumor activity in vivo (2006) (9)
Antiidiotypic responses to immunization with anti-Leu 3a in human immunodeficiency virus-seropositive individuals. (1991) (9)
Immunobiological aspects of HIV treatment. (1993) (9)
Lymphokine-activated killer cell activity in rheumatoid arthritis. (1987) (8)
Current problems in the development of specific immunotherapeutic approaches to cancer. (2001) (8)
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial (2019) (8)
Immunotherapy of murine prostate cancer using whole tumour cells killed ex vivo by cytosine deaminase/5‐fluorocytosine suicide‐gene therapy (2005) (8)
Human immunodeficiency virus (HIV) infection in the regular sexual partners of homosexual men with AIDS and persistent generalised lymphadenopathy (1987) (8)
The importance for immunoregulation for long-term cancer control. (2017) (8)
Refractory hypercalcaemia (1984) (8)
Tumor immunology : immunotherapy and cancer vaccines (1996) (8)
Prospects for Vaccination in Prostate Cancer (2000) (8)
A multicenter randomized, open-label, proof-of-concept, phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer. (2015) (8)
A viral etiology for Hodgkin's disease? (1986) (8)
Retroviruses in rheumatoid arthritis. (1986) (8)
Tripartite immune cell co‐operation in the Bacillus Calmette Guérin‐induced activation of γδ T cells (2013) (7)
Analysis of K-ras gene mutations in human pancreatic cancer cell lines and in bile samples from patients with pancreatic and biliary cancers. (1997) (7)
The role of HIV gp120 in the disruption of the immune system. (1999) (7)
Search for a retroviral cause for sarcoidosis: no evidence from peripheral blood studies. (1991) (7)
Human T leukaemia virus type 1 (HTLV‐1) specific T‐helper cell response: clonal fluctuations and repertoire heterogeneity (1996) (7)
Biomarkers for the Development of Cancer Vaccines (2006) (7)
Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study (2010) (7)
HIV and CD26 (1995) (7)
Abnormal cytokine profiles inpatients with idiopathic dilated cardiomyopathy andtheir asymptomaticrelatives (1996) (7)
The cytotoxic molecule granulysin is capable of inducing either chemotaxis or fugetaxis in dendritic cells depending on maturation: a role for Vδ2+ γδ T cells in the modulation of immune response to tumour? (2020) (7)
Differential expression of melanoma-associated antigens and molecules involved in antigen processing and presentation in three cell lines established from a single patient (2004) (7)
The role of hepatitis B virus in the etiology of hepatocellular carcinoma in Australia. (1983) (7)
Aetiology of AIDS (1993) (7)
Immunomodulatory agents: the cytokines. (1994) (7)
Lack of T cell response to cardiac myosin and a reduced response to PPD in patients with idiopathic dilated cardiomyopathy. (1997) (7)
Hypertrophic pulmonary osteoarthropathy: response to chemotherapy without documented tumour response. (1983) (7)
Cytokines in the genesis and treatment of cancer (2007) (7)
The potential beneficial effects of drugs on the immune response to vaccination. (2012) (6)
Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells (2020) (6)
The development of therapeutic vaccines of the management of malignant melanoma. (1996) (6)
The role of herpes simplex virus thymidine kinase in the treatment of solid tumours. (1999) (6)
Supernatants derived from chemotherapy-treated cancer cell lines can modify angiogenesis (2012) (6)
The Pathogenesis of AIDS: Classical and Alternative Views (1992) (6)
The Evidence which Suggests that This Is No Naturally Evolved Virus A Reconstructed Historical Aetiology of the SARS-CoV-2 Spike (2020) (6)
Case report on the role of radiofrequency-assisted spleen-preserving surgery for splenic metastasis in the era of check-point inhibitors (2017) (6)
Revisiting the role of systemic therapies in patients with metastatic melanoma to the CNS (2013) (6)
Disease Regression in Malignant Melanoma: Spontaneous Resolution or a Result of Treatment With Antioxidants, Green Tea, and Pineapple Cores? A Case Report (2007) (6)
Ipilimumab in the real world: The UK expanded access programme (EAP) experience in advanced melanoma. (2013) (5)
Novel immunotherapeutic approaches to prostate cancer. (2005) (5)
Combination Therapy in Cancer (2016) (5)
Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study) (2013) (5)
Cytokine gene transfection for autologous and allogeneic melanoma vaccines. (2001) (5)
A heat-killed preparation of mycobacterium obuense can reduce metastatic burden in vivo (2014) (5)
Vascular endothelium: a potential role in HIV infection and the pathogenesis of Kaposi's sarcoma: observations and speculations. (1991) (5)
Infection and cancer (2001) (5)
Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer (2020) (5)
Human retroviruses and paediatric disease. (1987) (5)
Immunotherapy with Mycobacterium vaccae (1999) (5)
IS STAGING LAPAROTOMY NECESSARY IN PATIENTS WITH SUPRADIAPHRAGMATIC STAGE I AND IIA HODGKIN'S DISEASE? (1984) (5)
Cancer vaccines. (1994) (5)
Pancytopaenia and Hepatosplenomegaly in an AIDS Patient Responding to High Dose Steroids (1992) (5)
Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma. (2014) (5)
Use of PCR to Investigate the Cellular Tropism of Human T Cell Leukemia Virus Type 1 (1991) (5)
Dendritic cell phenotype can be improved by certain chemotherapies and is associated with alterations to p21waf1/cip1 (2013) (5)
Increased time to progression and sustained PSA velocity responses in a phase II trial in advanced metastatic prostate cancer following treatment with ONY-P1, an allogeneic whole cell vaccine (2005) (5)
Normal and SV40 transfected human peritoneal mesothelial cells produce IL‐6 and IL‐8 : implication for gynaecological disease (2002) (5)
Cancer biologists hit the road. Molecular genetics of cancer: Second Joint Conference of the American Association for Cancer Research and the European Association for Cancer Research. Oxford, UK, 9-13 September 1997. Cancer gene therapy symposium. London, UK, 23-24 June 1997. (1997) (4)
Oncological applications of gene therapy. (2000) (4)
Human trials of AIDS vaccines: novel means of passive and active immunotherapy. (1988) (4)
The Immunomodulatory Drug (IMID®) CC-4047 Enhances the Proliferation and Anti-Tumor Function of Gamma Delta T Cells (2004) (4)
Evolution, immune response, and cancer (2000) (4)
Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer (2020) (4)
Absence of GVH Diseases in AIDS (1994) (4)
Abnormal Cytokine Levels in Idiopathic Dilated Cardiomyopathy Correlate with Prognosis (1995) (4)
Long term survival in IMAGE 1 (Immune Modulation And Gemcitabine Evaluation 1), a randomized, open-label phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer. (2015) (4)
AIDS, PORTUGAL, AND AFRICA (1986) (4)
Comparison of Anti-Angiogenic Activities of Thalidomide and Lenalidomide In Vitro. (2005) (4)
The immuno-oncological implications of insulin. (2020) (4)
Human immunodeficiency virus and the immunology of infection. (1992) (4)
Correlation of Antibody Responses to a Peptide Antigen gp120-C5501-512/gp41732-744 with HIV Disease Progression. (2017) (4)
Acquired immune deficiency syndrome: A prodromal form (1983) (4)
Therapeutic cancer vaccines. (2007) (4)
Hepatocellular carcinoma associated with hepatitis B in a renal graft recipient (1983) (4)
Serum Apolipoprotein E and Other Inflammatory Markers Can Identify Non-Responding Patients to a Dendritic Cell Vaccine12 (2018) (4)
Biomarkers for development of cancer vaccines. (2006) (3)
T-cell receptor variable gen products and early HIV-1 infection : authors replies (1992) (3)
Subtle Mimicry of HLA by HIV-1 GP120 – A Role for Anti HLA Antibodies? (2010) (3)
The human oncogenic viruses edited by A. Luderer and H. Weethall, Humana Press Inc., US$59.50 (xv + 281 pages) ISBN 0 89603 1. (1987) (3)
Overcoming technical challenges in the development of cancer vaccines. (2007) (3)
Corrigendum: Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine (Gene Therapy (1999) 6 (1475-1481)) (1999) (3)
Detection of T Cell Cytokine Production as a Tool for Monitoring Immunotherapy (2002) (3)
Anti-idiotypic therapeutic strategies in HIV infection. (1992) (3)
Genetically modified tumour cells for cancer immunization (2001) (3)
The Power of the Web in Cancer Drug Discovery and Clinical Trial Design: Research without a Laboratory? (2010) (3)
The impact of biotechnology on autoimmunity (1993) (3)
Small Molecule Therapeutics The Combination of Cannabidiol and D 9-Tetrahydrocannabinol Enhances the Anticancer Effects of Radiation in an Orthotopic Murine Glioma Model (2014) (3)
Study of immunological and virological parameters during thalidomide treatment of SIV‐infected cynomolgus monkeys (2000) (3)
The Potential Role of HLA Mimicry in the Pathogenesis of AIDS (1999) (3)
27PFive year survival in patients with metastatic melanoma receiving IMM-101 (2015) (3)
The Role of Tregs in Cancer: Foxp3 as a Putative Target for Therapy (2009) (3)
HIV and tropism: implications for pathogenesis. (1991) (3)
Antiviral Strategies and Vaccines against HTLV III/LAV (1986) (3)
Immunotherapy and the development of cancer vaccines (2006) (3)
Gemcitabine in the Era of Cancer Immunotherapy (2020) (3)
3-Fold increase in survival for stage IV melanoma patients treated with MCV allogeneic vaccine: confirmation of previous phase II data (1999) (3)
Should we be using 5-HT3 antagonists as first line antiemetic therapy in cisplatin-based chemotherapy? (1993) (3)
Directing T-Cell Immune Responses for Cancer Vaccination and Immunotherapy (2021) (2)
IMM-101, an immunotherapeutic agent in clinical development as an adjunctive treatment for pancreatic cancer (2014) (2)
The potential importance of MHC mimicry by HIV in the pathogenesis of AIDS. (1995) (2)
Cancer cell-derived supernatants that support the carcinogenic process: a future cancer therapy target? (2012) (2)
Abstract 5418: The immunomodulatory drug lenalidomide restores a Vitamin D sensitive phenotype to the Vitamin D resistant breast cancer cell line MDA-MB-231: Potential for breast cancer therapeutics (2010) (2)
Abstract 5386: Lenalidomide enhances the anti-prostate cancer activity of docetaxelin vitroandin vivo (2010) (2)
Human retroviruses. (1988) (2)
Pilot study on the treatment of AIDS and ARC patients with intravenous foscarnet [abstract] (1986) (2)
Monthly Update: Biologicals & Immunologicals: New drugs for the treatment of HIV infection (1995) (2)
The immunotherapy of prostate cancer (2000) (2)
Tumour markers in malignancies. CA19.9 is useful in several cancers. (2000) (2)
The gp120 envelope of HIV-1 binds and presents peptides in a similar manner to human leukocyte antigen. (1999) (2)
Selection and T-cell antigenicity of synthetic long peptides derived from SARS-CoV-2 (2022) (2)
Molecular mechanisms underlying gemcitabine resistance in pancreatic cancer and restoration of sensitivity using lenalidomide. (2010) (2)
HIV-1 Step Study (2009) (2)
Identification of circulatory biomarkers from clinical trial samples (2015) (2)
Neutralization and receptor recognition of human T-lymphotropic retroviruses. (1987) (2)
Running head : Genomic subtypes of CFS / ME Seven genomic subtypes of Chronic Fatigue Syndrome / Myalgic Encephalomyelitis ( CFS / ME ) : a detailed analysis of gene networks and clinical phenotypes (2007) (2)
Effect of lenalidomide on the antiproliferative effect of gemcitabine against pancreatic tumor cells and on immune-mediated pancreatic cancer cell death. (2016) (2)
Abstract 5612: Pretreatment with chemotherapy can enhance the immunogenicity of tumors by promoting adaptive immune responses (2010) (2)
Human T-cell lymphotrophic virus type 1: infections and pathogenesis. (1998) (2)
LACTICACIDOSIS OF THIAMINE DEFICIENCY (1984) (2)
WITHDRAWN: Goat serum product "Aimspro" restores conduction in demyelinated human optic nerve fibres. (2006) (2)
B109 Vacc-4x and Vacc-C5: Two peptide-based therapeutic HIV vaccine candidates (2013) (2)
Corrigendum: Adjuvant bevacizumab for melanoma patients at high risk of recurrence: Survival analysis of the AVAST-M trial (Annals of Oncology (2018) 29:8 (1843-1852) DOI: 10.1093/annonc/mdy229) (2020) (2)
Recent progress in immunotherapy: anti-cancer vaccines, emerging clinical data. (2008) (2)
AIDS: clinical and scientific issues past, present and future. (1995) (2)
Bacillus Calmette-Guerin (BCG) induces superior anti-tumour responses by Vδ2+ T cells compared with the aminobisphosphonate drug zoledronic acid (2022) (2)
Dendritic cell immunotherapy for metastatic prostate cancer using cryopreserved dendritic cells pulsed with allogeneic tumour lysate (2002) (1)
Evaluation of commercially available assays of neopterin and beta 2-microglobulin for the assessment of disease progression in FIV-infected cats. (1997) (1)
Chapter 9 HIV Induced AIDS and Related Cancers (2008) (1)
Effect of the Modification of p24 Peptide Antigen on Dendritic Cell Uptake and T Cell Activation. (2017) (1)
1015 Activity of the MAPK signalling cascade correlates to gemcitabine sensitivity in pancreatic cancer cells (2009) (1)
Supernatants of tumours treated with chemotherapy can alter tumour growth and development in vivo. (2015) (1)
Why do the majority of patients not respond at all, or only partially or transiently, to immunotherapy? (2019) (1)
Cancer and Inflammation (2005) (1)
Goat serum product restores conduction in demyelinated human optic nerve fibres (2007) (1)
Interview with Professor Angus Dalgleish. (2016) (1)
Priming of Human CD 4 1 Antigen-specific T Cells to Undergo Apoptosis by HIV-infected Monocytes A Two-step Mechanism Involving the gp 120 Molecule (2013) (1)
Overview of Cancer Vaccines (2009) (1)
Tumour markers in renal cell carcinoma (2003) (1)
The role of immune modulation and anti-inflammatory agents in the management of prostate cancer: A case report of six patients (2022) (1)
Vaccines: A rapidly evolving technology – Are the hurdles being addressed? (2007) (1)
Soluble CD4 enhances antiviral activity of anti-HIV serum in vitro. (1991) (1)
HTLV-I/II AND T-CELL PROLIFERATION (1985) (1)
Cancer vaccines (2000) (1)
Is Crohn's disease caused by a lymphotropic virus? (1986) (1)
Naltrexone at low doses (LDN) and its relevance to cancer therapy (2022) (1)
1103 Supernatant from tumour cells treated with chemotherapy stimulate professional antigen presenting cells in vitro (2009) (1)
The immunology of retrovirus disease. (1992) (1)
Mycobacterial immunotherapy for prostate cancer: where can we go from here? (2020) (1)
The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics (2011) (1)
Recent Pharmacological Advances: Focus on Small-cell Lung Cancer (2010) (1)
Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells (2013) (1)
Human Immunodeficiency Viruses (1998) (1)
Allogeneic Whole‐Cell Vaccines (2007) (1)
Long-term cure after complete resection and adjuvant immunotherapy for distant melanoma metastases (2012) (1)
Effect of lenalidomide on the antiprostate cancer activity of docetaxel in vitro and in vivo. (2010) (1)
The efficacy of chemotherapeutic drug combinations may be predicted by concordance of gene response to the single agents (2020) (1)
T-cell receptor variable gene products and early HIV-1 infection (1992) (1)
Synergistic growth inhibition of human pancreatic cancer cells following treatment with a combination of ErbB family blocker afatinib and IGF-IR inhibitor NVP-AEW541 (2013) (1)
Gene Encodes the AIDS Virus Recepto ressed in the Immune System and the Brain (2003) (1)
The successful treatment of metastatic androgen receptor-positive tumours of parotid origin with androgen receptor blockade and immunotherapy. (2019) (1)
Abstract 2833: The protein ps20 increases tumourigenic potential in prostate cancer epithelial cells (2012) (1)
Vaccines past, present and future (1995) (1)
Tropical Spastic Paraparesis & HTLV-1: Viral Prevalence among Relatives of UK Patients in Britain & Jamaica (1988) (1)
Editorial: Immunotherapy for Prostate Cancer – turning the immunological desert into an oasis of hope (2022) (1)
Use of human cell lines of the prostate to treat prostate cancer. (1999) (0)
Faculty Opinions recommendation of Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. (2014) (0)
asymptomatic relatives . idiopathic dilated cardiomyopathy and their Abnormal cytokine profiles in patients with (2003) (0)
Immunotherapy of AIDS. (1992) (0)
NEUROSIS DIVISIBLE AND SLE (1985) (0)
P-C1 Development of HIV-1 Immunotherapy with Vacc4x and Vacc-C5 (2018) (0)
COMPARISON BETWEEN TROPICAL SPASTIC PARAPARESIS AND MULTIPLE-SCLEROSIS USING EVOKED-POTENTIALS, MRI SCANNING AND HTLVI ANTIBODY ANALYSIS (1988) (0)
Points: Carcinoid tumour secreting dopa (1984) (0)
Virus Interaction with Host Cell Receptors: Does gp120 of Human Immunodeficiency Virus Resemble an MHC Class II Alloepitope? (1992) (0)
Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity (2018) (0)
Immunological uses of immunomodulatory compounds for vaccines and therapy of anti-infectious diseases. (2006) (0)
IMMUNOTHERAPY WITH MYCOBACTERIUM VACCAE. AUTHORS' REPLY (1999) (0)
Chapter 27 Genetics and molecular biology of AIDS virus (1998) (0)
Thalidomide, lenalidomide and pomalidomide reduce the metastatic capability of cancer cells in vivo and in vitro (2008) (0)
Therapeutic and diagnostic applications of monoclonal antibodies in pancreatic cancer: Advances and challenges (2017) (0)
Modulation of the adaptive immune system through chronic inflammation and T-regulatory responses (2014) (0)
Abstract 5758: Generation and characterization of novel monoclonal antibodies against overexpressed CD109 on pancreatic cancer cells for use in diagnosis and therapy (2018) (0)
Dendritic Cell Immunotherapy for Advanced Metastatic Melanoma: Interim Report (2005) (0)
The Bolter's brother in law (1984) (0)
HIV types and testing. (1991) (0)
The Role of HLA Mimicry by HIV in the Pathogenesis of Aids (1994) (0)
Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy (2023) (0)
712 Interleukin 10 polymorphism may predispose to renal cell cancer development (2004) (0)
The influence of primary colorectal cancer on immune function (1998) (0)
Abstract B13: Immunogenic chemotherapy alters microbiome-induced T-cell activation (2020) (0)
118 Responses of human pancreatic tumour cells to treatment with anti-EGFR mAb ICR62 and the irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor BIBW2992 (2010) (0)
Abstract 4233: The protein ps20 increases resistance to docetaxel in PC3 and LNCAP prostate cancer cell lines (2012) (0)
The novel anti-cancer agent curcumin induces cytotoxicity in pancreatic cancer cell lines in vitro (2008) (0)
FAMILIAL MEDITERRANEAN FEVER IN AUSTRALIA (1980) (0)
Interleukin 10 polymorphism may influence renal cancer development. (2003) (0)
Faculty Opinions recommendation of Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs. (2014) (0)
Faculty Opinions recommendation of A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. (2014) (0)
THE CHEMOTHERAPY OF SOLID TUMOURS (1978) (0)
Potential of the anti-idiotype approach for the development of an anti-HIV vaccine (1989) (0)
The authors reply as follows (1995) (0)
Co-targeting of HER family members and IGF-IR in pancreatic cancer (2013) (0)
Chemotherapy for solid tumours (1995) (0)
A randomized phase II trial of SRL172 (Mycobacterium vaccae) 6 low-dose interleukin-2 in the treatment of metastatic malignant melanoma (2003) (0)
Treatment of diseases of the nervous system with goat serum. (2003) (0)
Chemotherapy against human immunodeficiency virus infection. (1991) (0)
S38. Many reasons for combining immunotherapy with chemotherapy to enhance anti tumour response (2014) (0)
Anti-idiotype vaccines tackle colorectal cancer (1996) (0)
Markery nowotworowe w raku nerki Tumour markers in renal cell carcinoma (2002) (0)
Results of a phase II pilot study of 13-cis-retinoic acid with gemcitabine in patients with unresectable pancreatic cancer (2005) (0)
Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer (2020) (0)
Science challenging AIDS, 7th International Conference on AIDS, Florence, June 1991: Edited by G.B. Rossi, E. Beth-Giraldo, L. Chieco-Bianchi, F. Dianzani, G. Giraldo and P. Verani. 1992. ISBN 3-8055-5485-0. SFr. 120,-/DM 144,-/£ 52.20/US$96.00. (1992) (0)
ErratumErratum to “Successful live cell harvest from bisected sentinel lymph nodes research report” [J. Immunol. Methods 291 (2004) 71–78] (2004) (0)
Abstract 3426: Curcumin is effective in killing gemcitabine resistant pancreatic cancer cells: Studies of the cell cycle, and apoptosis. (2013) (0)
Effects of thalidomide therapy in symptomatic simian immunodeficiency virus-infected cynomolgus monkeys. (1998) (0)
Interleukin 10 polymorphism may influence renal cell cancer development (2003) (0)
Strategies to improve murine melanoma allogeneic vaccine using cytokine gene transfection (2002) (0)
Faculty Opinions recommendation of Interleukin-21 administration to rhesus macaques chronically infected with simian immunodeficiency virus increases cytotoxic effector molecules in T cells and NK cells and enhances B cell function without increasing immune activation or viral replication. (2014) (0)
I-107 Optimisation of a therapeutic vaccine; the importance of immune modulation (2018) (0)
Advances in Viral Oncology. Volume 5, Viruses as the Causative Agents of Naturally Occurring Tumors.George Klein (1986) (0)
174 The C5 region of gp120: A therapeutic vaccine target? (2009) (0)
Abstract 2582: Cytotopic IL-15 as a novel therapeutic for prostate cancer (2014) (0)
Combination of cannabidiol with low‑dose naltrexone increases the anticancer action of chemotherapy in vitro and in vivo. (2022) (0)
Medical Therapy of Breast Cancer: New immunological approaches to treatment for breast cancer (2003) (0)
Abstract 630: Responses of human pancreatic cancer cells to treatment with insulin-like growth factor receptor (IGF-IR) tyrosine kinase inhibitor NVP-AEW541 alone and in combination with anti-EGFR mAb ICR62 or cytotoxic drugs (2011) (0)
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. (2019) (0)
1102 Chemotherapy increases HLA-ABC expression on tumour cells and promotes allogeneic cytotoxic responses (2009) (0)
Using polyclonal serum anti-HIV goat as a therapeutic agent. (2002) (0)
Thrombophlebitis migrans following co-trimoxazole therapy. (1989) (0)
Activation-Induced TNF-Thalidomide and Potent Inhibitor of CC-3052 : A Water-Soluble Analog of (1998) (0)
Abstract A43: Lenalidomide enhances the anti-proliferative activity of docetaxel in in vivo and in vitro models of prostate cancer (2010) (0)
Effect of carboplatin when administered after dacarbazine failure: Clinical benefit of sequential therapy. (2020) (0)
Editorial Board Focus – February 2007 (2007) (0)
Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma (2019) (0)
Retinoids: From basic science to clinical applications: Edited by M A Livrea and G Vidali, pp 396. Birkhäuser, Basel. 1994. SF 128 ISBN 3-7643-2812-6 (1995) (0)
Recombinant HTLV-1 envelope fails to stimulate human T-cells (2007) (0)
Human retroviruses: human T-cell leukaemia lymphoma virus (HTLV-I) and disease (1989) (0)
I m m u n o t h e r a py with Mycobacterium va c c a e (1999) (0)
Novel strains of as potential vectors for gene delivery (2004) (0)
Active Immunotherapy for Solid Tumours (1997) (0)
Cells as Vaccines (2007) (0)
836 Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy (2020) (0)
Uses for an anti-HLA antibody and a goat serum composition (2002) (0)
PC-8 Novel chemoimmunotherapy combinations for pancreatic cancer (2019) (0)
INHIBITION OF P38 MAP KINASE DURING ACTIVATION OF PBMC LEADS TO ENHANCED PRODUCTION OF IL-12P40/P70 (1999) (0)
Comprar Tumor Immunology | A. G. Dalgleish | 9780521159470 | Cambridge University Press (2010) (0)
Points: AIDS: an old disease from Africa? (1984) (0)
The CD4 Loss in AIDS Patients is Immunopathologically Mediated (1996) (0)
Faculty Opinions recommendation of A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. (2014) (0)
New multitargeted treatments with antiangiogenic and antitumor activity: focus on sunitinib (2007) (0)
Cancer vaccines from melanoma to ovarian cancer: good immune responses obtained (2007) (0)
Abstract B38: Non-cytotoxic effects of the chemotherapeutic agent gemcitabine can alter the immunophenotype of tumor cells in in vitro culture (2017) (0)
AIDS Portugal and Africa [letter] (1986) (0)
Millennium mini-review (2017) (0)
Faculty Opinions recommendation of Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. (2014) (0)
Identification of putative biomarkers in cancer therapy (2011) (0)
Acknowledgement to Reviewers (2005) (0)
A unified hypothesis for three cardinal features of HIV immunology: authors' reply. (1991) (0)
Title : In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents Authors : (2011) (0)
Abstract 2691: Expression pattern and prognostic significance of HER family members and EGFRvIII in pancreatic cancer (2022) (0)
Erratum: Repertoire breadth of human CD4+ T cells specific for HIV gp120 and p66 (primary antigens) or for PPD and tetanus toxoid (secondary antigens) (Human Immunology (1998) 59 (137)) (1998) (0)
410 Predictive Value of CD44, CD24, CD133 and P-glycoprotein for Response to Treatment With a Pan ErbB Blocker and Gemcitabine in Pancreatic Tumour Cells (2012) (0)
O-003IMM-101 Extends Survival and Maintains Quality of Life in IMAGE 1, a Randomized, Open-label Phase II Trial comparing Gemcitabine with and without IMM 101 in advanced pancreatic cancer (2015) (0)
PO-043 Development of two novel monoclonal antibodies against overexpressed antigens on pancreatic cancer cells for use in diagnosis and therapy (2018) (0)
Fifth International Conference on AIDS : the Scientific and Social Challenge; symposium; role of macrophages and lymphocytes as reservoirs of HIV-1 (1989) (0)
DNA vaccines (2000) (0)
J.Verne-Pignatelli, (1989) (0)
A novel marine model of allogeneic vaccination against prostate cancer. (2002) (0)
Suicide gene therapy in the rat model of prostate cancer (1999) (0)
The C5 region of HIV-1 gp120 binds specific (2006) (0)
The immunomodulatory drugs target proliferation in T-cells via the cyclin-dependent kinase inhibitor p21 (2016) (0)
Antiangiogenic Therapy for Melanoma (2007) (0)
The effect Thalidomide analogue CC-3052 on mitogen-induced TNF-α/cytokine production ex vivo (1997) (0)
P-C14 Association of anti-Vacc-C5 antibody titre with immune function and immune activation in HIV-1 infected subjects (2017) (0)
The Third Institute for Cancer Vaccines and Immunotherapy (ICVI) symposium on immunotherapy: May 12–13, 2017, Royal Society, London, UK (2018) (0)
Immunological uses of immunomodulatory compounds for a vaccine and treatment against infectious diseases (2006) (0)
The role of adenoviral vectors in genetic prodrug activation therapy in prostate cancer (2000) (0)
An anti-idiotype vaccine for AIDS based on the HIV receptor. (1991) (0)
Practical Aspects in the Use of Biomarkers for the Development of Cancer Vaccines (2008) (0)
T4: A T-Cell Surface Protein Mediating Cell-Cell and Cell-AIDS Virus Interactions (1987) (0)
Melanoma vaccines. (2004) (0)
HTLV-I envelope proteins: Studies on topology and involvement in T-cell activation (2007) (0)
A10 The Potential Role of Antibodies to the C5 Domain of gp120 in Mitigating Generalized Immune Activation Associated With HIV-1 Infection (2012) (0)
In vitro culture with gemcitabine augments death receptor and NKG2D ligand expression on tumour cells (2019) (0)
Cancer 2025: Prevention (2004) (0)
Immunological uses of immunomodulatory compounds of the vaccine and therapy of infectious diseases (2006) (0)
Faculty Opinions recommendation of Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. (2014) (0)

This paper list is powered by the following services:

Other Resources About Angus Dalgleish

en.wikipedia.org

What Schools Are Affiliated With Angus Dalgleish?

Angus Dalgleish is affiliated with the following schools:

Angus Dalgleish's Academic­Influence.com Rankings